Rabeprazole in the treatment of acid-related disorders
DOI: 10.32364/2587-6821-2023-7-5-4
V.V. Tsukanov
Federal Research Center «Krasnoyarsk Science Center» of the Siberian Branch of the Russian Academy of Sciences, Krasnoyarsk, Russian Federation
Proton-pump inhibitors (PPIs) are widely used to treat acid-related disorders (ARD). Rabeprazole is a potent inhibitor of gastric H+/K+-ATPase, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger-Ellison syndrome, gastric and duodenal ulcers and for Helicobacter pylori eradication (in combination with antibiotics), as well as for the treatment of ARD described in this article. Pharmacokinetic and pharmacodynamic data show that rabeprazole provides a marked acid inhibition from the first administration, which persists with repeated use. Due to the predominantly non-enzymatic metabolism, rabeprazole has a lower interaction potential between drugs. Besides, rabeprazole maintains a high intragastric pH and achieves maximum acid inhibition in 24 hours. Rabeprazole is characterized by linearity of pharmacokinetics, which remains unchanged in renal and hepatic insufficiency. Rabeprazole is available in the dosage form of enteric capsules due to the PPIs instability in an acidic environment. Rabeprazole is generally well-tolerated by patients. Besides several minor side effects, rabeprazole is safe to be widely used in the treatment of ARD.
Keywords: proton pump inhibitors, antisecretory drugs, rabeprazole, efficacy, safety, expediency, acid-related disorders, gastroesophageal reflux disease, peptic ulcer, gastropathy, dyspepsia.
For citation: Tsukanov V.V. Rabeprazole in the treatment of acid-related disorders. Russian Medical Inquiry. 2023;7(5):264–273 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-4.
About the author:
Vladislav V. Tsukanov — Dr. Sc. (Med), Professor, Head of the Clinical Department of Digestive System Pathology in Adults and Children, Research Institute of Medical Problems in the North, Federal Research Center «Krasnoyarsk Science Center» of the Siberian Branch of the Russian Academy of Sciences; 3G, Partizan Zheleznyak Str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0002-9980-2294.
Contact information: Vladislav V. Tsukanov, e-mail: gastro@impn.ru.
Financial Disclosure: the author has no financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 07.04.2023.
Revised 28.04.2023.
Accepted 24.05.2023.
References
1. Scarpignato C., Pelosini I., Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis. 2006;24(1-2):11–46. DOI: 10.1159/000091298.
2. Hunt R.H. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005;22(Suppl 3):10–19. DOI: 10.1111/j.1365-2036.2005.02715.x.
3. Scarpignato C., Hunt R.H. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol. 2008;8(6):677–684. DOI: 10.1016/j.coph.2008.09.004.
4. Hunt R.H., Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6(10):e119. DOI: 10.1038/ctg.2015.39.
5. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72(4):437–445. DOI: 10.2165/11599320-000000000-00000.
6. Lanas A. We are using too many PPIs, and we need to stop: A European perspective. Am J Gastroenterol. 2016;111(8):1085–1086. DOI: 10.1038/ajg.2016.166.
7. Galmiche J.P. Traitement de l'oesophagite de reflux par les inhibiteurs de pompe à protons: de l'efficacité à la dépendance. Hépato-Gastro Oncol Digest. 1995;2:215–219.
8. Boath E.H., Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients' perspectives. Soc Sci Med. 1997;45(10):1571–1579. DOI: 10.1016/S0277-9536(97)00094-4.
9. Pottegård A., Broe A., Hallas J. et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9(5):671–678. DOI: 10.1177/1756283X16650156.
10. Cammarota S., Bruzzese D., Sarnelli G. et al. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42(10):1068–1078. DOI: 10.1111/j.1365-2362.2012.02696.x.
11. Inadomi J.M., Fendrick A.M. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3(3):208–215. DOI: 10.1016/S1542-3565(04)00717-7.
12. Haag S., Andrews J.M., Katelaris P.H. et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226–234. DOI: 10.1159/000235953.
13. Boardman H.F., Delaney B.C., Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin. 2015;31(7):1309–1318. DOI: 10.1185/03007995.2015.1047745.
14. Scarpignato C., Gatta L., Zullo A. et al. Effective and safe proton pump inhibitor therapy in acid-related diseases — A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. DOI: 10.1186/s12916-016-0718-z.
15. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. DOI: 10.1136/gutjnl-2015-309252.
16. Kromer W., Krüger U., Huber R. et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2):57–70. DOI: 10.1159/000028183.
17. Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г. Клиническая эффективность рабепразола. Медицинский алфавит. 2017;1(9):40–45. [Plotnikova E.Yu., Sukhikh A.S., Grachyova T.Yu., Vologzhanina L.G. Clinical efficacy of rabeprazole. Medical alphabet. 2017;1(9):40–45 (in Russ.)].
18. Swan S.K., Hoyumpa A.M., Merritt G.J. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther. 1999;13 Suppl 3:11–17. DOI: 10.1046/j.1365-2036.1999.00020.x.
19. Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother. 2004;5(1):137–149. DOI: 10.1517/14656566.5.1.137.
20. Furuta T., Shirai N., Sugimoto M. et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153–167. DOI: 10.2133/dmpk.20.153.
21. McColl K.E., Kennerley P. Proton pump inhibitors — differences emerge in hepatic metabolism. Dig Liver Dis. 202l;34(7):461–467. DOI: 10.1016/s1590-8658(02)80102-5.
22. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13 Suppl 3:27–36. DOI: 10.1046/j.1365-2036.1999.00022.x.
23. Fuhr U., Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie. 2002;57(9):595–601.
24. Besancon M., Simon A., Sachs G., Shin J.M. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438–22446. DOI: 10.1074/jbc.272.36.22438.
25. Ohning G.V., Walsh J.H., Pisegna J.R. et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther. 2003;17(9):1109–1114. DOI: 10.1046/j.1365-2036.2003.01573.x.
26. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99(2):345–351. DOI: 10.1016/0016-5085(90)91015-x.
27. Williams M.P., Sercombe J., Hamilton M.I., Pounder R.E. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12(11):1079–1089. DOI: 10.1046/j.1365-2036.1998.00418.x.
28. Pantoflickova D., Dorta G., Ravic M. et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507–1514. DOI: 10.1046/j.1365-2036.2003.01496.x.
29. Saitoh T., Fukushima Y., Otsuka H. et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002;16(10):1811–1817. DOI: 10.1046/j.1365-2036.2002.01348.x.
30. Pehlivanov N.D., Olyaee M., Sarosiek I., McCallum R.W. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther. 2003;18(9):883–890. DOI: 10.1046/j.1365-2036.2003.01776.x.
31. Luo J.Y., Niu C.Y., Wang X.Q. et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol. 2003;9(11):2583–2586. DOI: 10.3748/wjg.v9.i11.2583.
32. Skoczylas T., Sarosiek I., Sostarich S. et al. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322–328. DOI: 10.1023/a:1021983611768.
33. Jaworski T., Sarosiek I., Sostarich S. et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357–365. DOI: 10.1007/s10620-005-1611-3.
34. Hall J., Dodd S., Durkin M., Sloan S. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care. 2002;11(7 Suppl):14–18.
35. Gardner J.D., Gallo-Torres H., Sloan S. et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18(9):891–905. DOI: 10.1046/j.1365-2036.2003.01777.x.
36. Miner P.Jr., Orr W., Filippone J. et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332–1339. DOI: 10.1111/j.1572-0241.2002.05769.x.
37. Damiano A., Siddique R., Xu X. et al. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;48(4):657–662. DOI: 10.1023/a:1022812103923.
38. Kahrilas P.J., Miner P., Johanson J. et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50(11):2009–2018. DOI: 10.1007/s10620-005-3000-3.
39. Fock K.M., Teo E.K., Ang T.L. et al. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005;11(20):3091–3098. DOI: 10.3748/wjg.v11.i20.3091.
40. Bour B., Staub J.L., Chousterman M. et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21(7):805–812. DOI: 10.1111/j.1365-2036.2005.02413.x.
41. Robinson M., Fitzgerald S., Hegedus R. et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445–454. DOI: 10.1046/j.1365-2036.2002.01181.x.
42. Adachi K., Hashimoto T., Hamamoto N. et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18(12):1392–1398. DOI: 10.1046/j.1440-1746.2003.03190.x.
43. Pace F., Annese V., Prada A. et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37(10):741–750. DOI: 10.1016/j.dld.2005.04.026.
44. Archimandritis A.J., Nikolopoulou V., Kouklakis G. et al. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. Curr Med Res Opin. 2005;21(4):603–610. DOI: 10.1185/030079905X41444.
45. Kinoshita Y., Hongo M.; Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107(4):522–530. DOI: 10.1038/ajg.2012.19.
46. Kinoshita Y., Kato M., Fujishiro M. et al. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol. 2018;53(7):834–844. DOI: 10.1007/s00535-017-1417-z.
47. Fujimoto K., Hongo M.; Maintenance Study Group. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern Med. 2011;50(3):179–188. DOI: 10.2169/internalmedicine.50.4238.
48. Xia X.M., Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:327571. DOI: 10.1155/2013/327571.
49. Adachi K., Hashimoto T., Hamamoto N. et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18(12):1392–1398. DOI: 10.1046/j.1440-1746.2003.03190.x.
50. Pace F., Pallotta S., Bianchi Porro G. On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease. Dig Liver Dis. 2002;34(12):870–877. DOI: 10.1016/s1590-8658(02)80259-6.
51. Inamori M., Togawa J., Takahashi K. et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol. 2003;18(9):1034–1038. DOI: 10.1046/j.1440-1746.2003.03126.x.
52. Bytzer P., Blum A., De Herdt D., Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20(2):181–188. DOI: 10.1111/j.1365-2036.2004.01999.x.
53. Birbara C., Breiter J., Perdomo C., Hahne W. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol. 2000;12(8):889–897. DOI: 10.1097/00042737-200012080-00008.
54. Thjodleifsson B., Beker J.A., Dekkers C. et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000;45(5):845–853. DOI: 10.1023/a:1005548318996.
55. Dean B.B., Siddique R.M., Yamashita B.D. et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm. 2001;58(14):1338–1346. DOI: 10.1093/ajhp/58.14.1338.
56. Gerson L.B., Shetler K., Triadafilopoulos G. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liver Dis. 2005;37(9):651–658. DOI: 10.1016/j.dld.2005.04.013.
57. Johnston M.H., Eastone J.A., Horwhat J.D. et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005;62(6):842–848. DOI: 10.1016/j.gie.2005.05.008.
58. Chang A.B., Lasserson T.J., Gaffney J. et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011;2011(1):CD004823. DOI: 10.1002/14651858.CD004823.pub4.
59. Haddad I., Kierkus J., Tron E. et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57(6):798–807. DOI: 10.1097/MPG.0b013e3182a4e718.
60. Gibson P.G., Henry R.L., Coughlan J.L. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;2:CD001496. DOI: 10.1002/14651858.CD001496.
61. Oda K., Iwakiri R., Hara M. et al. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci. 2005;50(10):1921–1926. DOI: 10.1007/s10620-005-2962-5.
62. Tsugeno H., Mizuno M., Fujiki S. et al. A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand J Gastroenterol. 2003;38(5):456–461. DOI: 10.1080/00365520310002490.
63. Kłopocka M., Sinkiewicz A., Budzyński J. et al. Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole. Med Sci Monit. 2004;10(10):PI115–PI118.
64. Swiatkowski M., Budzyński J., Kłopocka M. et al. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med Sci Monit. 2004;10(9):CR524–CR529.
65. Molina-Infante J., Bredenoord A.J., Cheng E. et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65(3):524–531. DOI: 10.1136/gutjnl-2015-310991.
66. Dellon E.S., Gonsalves N., Hirano I. et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–692; quiz 693. DOI: 10.1038/ajg.2013.71.
67. Lucendo A.J., Arias Á., Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22.e1. DOI: 10.1016/j.cgh.2015.07.041.
68. Cheng E. Proton pump inhibitors for eosinophilic oesophagitis. Curr Opin Gastroenterol. 2013;29(4):416–420. DOI: 10.1097/MOG.0b013e32835fb50e.
69. Gisbert J.P., Khorrami S., Calvet X., Pajares J.M. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17(6):751–764. DOI: 10.1046/j.1365-2036.2003.01450.x.
70. Mario F.D., Dal Bo N., Aragona G. et al. Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. J Gastroenterol Hepatol. 2003;18(7):783–786. DOI: 10.1046/j.1440-1746.2003.03035.x.
71. Gambaro C., Bilardi C., Dulbecco P. et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig Liver Dis. 2003;35(11):763–767. DOI: 10.1016/s1590-8658(03)00458-4.
72. Yang K.C., Wang G.M., Chen J.H. et al. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J Formos Med Assoc. 2003;102(12):857–862.
73. Giannini E.G., Bilardi C., Dulbecco P. et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2006;23(2):281–287. DOI: 10.1111/j.1365-2036.2006.02756.x.
74. Wang H.H., Chou J.W., Liao K.F. et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World J Gastroenterol. 2005;11(11):1680–1984. DOI: 10.3748/wjg.v11.i11.1680.
75. Vakil N., Lanza F., Schwartz H., Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20(1):99–107. DOI: 10.1111/j.1365-2036.2004.02029.x.
76. Kawabata H., Habu Y., Tomioka H. et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2003;17(2):259–264. DOI: 10.1046/j.1365-2036.2003.01406.x.
77. Gisbert J.P., Pajares J.M. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21(7):795–804. DOI: 10.1111/j.1365-2036.2005.02418.x.
78. Ando T., Kato H., Sugimoto N. et al. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci. 2005;50(9):1625–1631. DOI: 10.1007/s10620-005-2907-z.
79. Ji S., Kim H.S., Kim J.W. et al. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J Gastroenterol Hepatol. 2006;21(9):1381–1387. DOI: 10.1111/j.1440-1746.2006.04314.x.
80. Kuo C.H., Wang S.S., Hsu W.H. et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265–272. DOI: 10.1111/j.1523-5378.2010.00761.x.
81. Viola M.J., Kondaveti S. To Compare the Safety and Efficacy of Three different, Proton Pump Inhibitors Omeprazole, Esomeprazole and Rabe-prazole in a Triple Drug Regimen in Patients with Peptic Ulcer Disease in the Eradication of H. Pylori Infection. Journal of Evidence based Medicine and Healthcare. 2015;2(13):2007–2026. DOI: 10.18410/jebmh/2015/285.
82. Sapmaz F., Kalkan I.H., Atasoy P. et al. A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. Am J Ther. 2017;24(4):e393–e398. DOI: 10.1097/MJT.0000000000000316.
83. Русяев В.Ю., Шептулин Д.А., Шульпекова Н.В., Шульпекова Ю.О. Рабепразол в лечении язвенной болезни двенадцатиперстной кишки и функциональной диспепсии. Медицинский совет. 2018;12:70–76. DOI: 10.21518/2079-701X-2018-12-70-76. [Rusyaev V.Yu., Sheptulin D.A., Shulpekova N.V., Shulpekova Yu.O. Rabeprazole in the treatment of duodenal ulcer desease and functional dyspepsia. Meditsinskiy sovet. 2018;12:70–76 (in Russ.)]. DOI: 10.21518/2079-701X-2018-12-70-76.
84. Gu L., Li S., He Y. et al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter. 2019;24(4):e12594. DOI: 10.1111/hel.12594.
85. Nguyen L.T., Nguyen V.B., Tran T.V. et al. Efficacy of Helicobacter pylori Eradication Based on Rabeprazole–Bismuth–Tetracycline–Tinidazole Regimen in Vietnamese Patients with Duodenal Ulcers. Gastroenterology Insights. 2022;13(4):365–376. DOI: 10.3390/gastroent13040036.
86. Morocutti A., Merrouche M., Bjaaland T. et al. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther. 2006;24(10):1439–1444. DOI: 10.1111/j.1365-2036.2006.03137.x.
87. Iwakiri R., Tominaga K., Furuta K. et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38(7):729–740. DOI: 10.1111/apt.12444.
88. Yap P.R., Mahadeva S., Goh K.L. Commentary: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38(10):1321–1322. DOI: 10.1111/apt.12497.
89. Sud R., Pebbili K.K., Desai S.A. et al. Dyspepsia — The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study). J Assoc Physicians India. 2023;71(4):36–43. DOI: 10.5005/japi-11001-0231.
90. Sugimoto M., Nishino M., Kodaira C. et al. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol. 2010;50(3):320–330. DOI: 10.1177/0091270009344983.
91. Nishino M., Sugimoto M., Kodaira C. et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci. 2010;55(6):1627–1636. DOI: 10.1007/s10620-009-0920-3.
92. Mizokami Y. Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan. World J Gastroenterol. 2009;15(40):5097–5102. DOI: 10.3748/wjg.15.5097.
93. Scarpignato C., Gatta L., Zullo A., Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases — A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. DOI: 10.1186/s12916-016-0718-z.
94. Плотникова Е.Ю., Исаков Л.К., Синькова М.Н., Гуляева Е.Н. Гастроинтестинальные кровотечения на фоне приема антикоагулянтов: риск возникновения, профилактика и лечение. Терапия. 2020;7:43–53. DOI: 10.18565/therapy.2020.7.43-53. [Plotnikova Ye.Yu., Isakov L.K., Sin'kova M.N., Gulyayeva Ye.N. Gastrointestinal bleeding against the background of taking anticoagulant drugs: risk of occurrence, prevention and treatment. Therapy. 2020;7:43–53 (in Russ.)]. DOI: 10.18565/therapy.2020.7.43-53.
95. Geus W.P. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol Suppl. 2000;(232):10–20. PMID: 11232484.
96. Green F.W. Jr, Kaplan M.M., Curtis L.E., Levine P.H. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978;74(1):38–43. PMID: 21830.
97. Patchett S.E., Enright H., Afdhal N. et al. Clot lysis by gastric juice: an in vitro study. Gut. 1989;30(12):1704–1707. DOI: 10.1136/gut.30.12.1704.
98. Uedo N., Takeuchi Y., Yamada T. et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007;102(8):1610–1616. DOI: 10.1111/j.1572-0241.2007.01197.x.
99. Hopkins A.M., Kichenadasse G., McKinnon R.A. et al. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2022;126(1):42–47. DOI: 10.1038/s41416-021-01606-4.
100. Mehta D.R., Maseeh A. Prevention of acid aspiration during surgery for cancer using I.V rabeprazole. Journal of Clinical Oncology. 2005;23(16):8275–8275. DOI: 10.1200/jco.2005.23.16_suppl.8275.
101. Evans C.E., Peng Y., Zhu M.M. et al. Rabeprazole Promotes Vascular Repair and Resolution of Sepsis-Induced Inflammatory Lung Injury through HIF-1α. Cells. 2022;11(9):1425. DOI: 10.3390/cells11091425.
102. Zhou Y., Chen S., Yang F. et al. Rabeprazole suppresses cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis. Biochem Pharmacol. 2021;188:114525. DOI: 10.1016/j.bcp.2021.114525.
103. Miyashita T., Shah F.A., Marti G.P. et al. Rabeprazole Impedes the Development of Reflux-Induced Esophageal Cancer in a Surgical Rat Model. Dig Dis Sci. 2011;56:1309–1314. DOI: 10.1007/s10620-010-1465-1.
104. Gu M., Zhang Y., Zhou X. et al. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 2014;8(4):1739–1744. DOI: 10.3892/ol.2014.2354.
105. Lodato F., Azzaroli F., Di Girolamo M. et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol. 2008;14(19):2980–2985. DOI: 10.3748/wjg.14.2980.
106. Mahmud N., Serper M., Taddei T.H., Kaplan D.E. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology. 2022;163(1):257–269.e6. DOI: 10.1053/j.gastro.2022.03.052.
107. Sablin O.A., Ratnikov V.A., Butenko E.V., Pakhomova I.G. Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita [Clinical aspects of using pariet in treating chronic pancreatitis]. Eksp Klin Gastroenterol. 2002;(5):73–76, 129 (in Russ.). PMID: 12619583.
108. Yamawaki H., Futagami S., Kaneko K., Agawa S. et al. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion. 2019;99(4):283–292. DOI: 10.1159/000492813.
109. Baldwin C.M., Keam S.J. Rabeprazole. Drugs. 2009;69:1373–1401. DOI: 10.2165/00003495-200969100-00007.
2. Hunt R.H. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005;22(Suppl 3):10–19. DOI: 10.1111/j.1365-2036.2005.02715.x.
3. Scarpignato C., Hunt R.H. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol. 2008;8(6):677–684. DOI: 10.1016/j.coph.2008.09.004.
4. Hunt R.H., Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6(10):e119. DOI: 10.1038/ctg.2015.39.
5. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72(4):437–445. DOI: 10.2165/11599320-000000000-00000.
6. Lanas A. We are using too many PPIs, and we need to stop: A European perspective. Am J Gastroenterol. 2016;111(8):1085–1086. DOI: 10.1038/ajg.2016.166.
7. Galmiche J.P. Traitement de l'oesophagite de reflux par les inhibiteurs de pompe à protons: de l'efficacité à la dépendance. Hépato-Gastro Oncol Digest. 1995;2:215–219.
8. Boath E.H., Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients' perspectives. Soc Sci Med. 1997;45(10):1571–1579. DOI: 10.1016/S0277-9536(97)00094-4.
9. Pottegård A., Broe A., Hallas J. et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9(5):671–678. DOI: 10.1177/1756283X16650156.
10. Cammarota S., Bruzzese D., Sarnelli G. et al. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42(10):1068–1078. DOI: 10.1111/j.1365-2362.2012.02696.x.
11. Inadomi J.M., Fendrick A.M. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3(3):208–215. DOI: 10.1016/S1542-3565(04)00717-7.
12. Haag S., Andrews J.M., Katelaris P.H. et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226–234. DOI: 10.1159/000235953.
13. Boardman H.F., Delaney B.C., Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin. 2015;31(7):1309–1318. DOI: 10.1185/03007995.2015.1047745.
14. Scarpignato C., Gatta L., Zullo A. et al. Effective and safe proton pump inhibitor therapy in acid-related diseases — A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. DOI: 10.1186/s12916-016-0718-z.
15. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. DOI: 10.1136/gutjnl-2015-309252.
16. Kromer W., Krüger U., Huber R. et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2):57–70. DOI: 10.1159/000028183.
17. Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г. Клиническая эффективность рабепразола. Медицинский алфавит. 2017;1(9):40–45. [Plotnikova E.Yu., Sukhikh A.S., Grachyova T.Yu., Vologzhanina L.G. Clinical efficacy of rabeprazole. Medical alphabet. 2017;1(9):40–45 (in Russ.)].
18. Swan S.K., Hoyumpa A.M., Merritt G.J. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther. 1999;13 Suppl 3:11–17. DOI: 10.1046/j.1365-2036.1999.00020.x.
19. Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother. 2004;5(1):137–149. DOI: 10.1517/14656566.5.1.137.
20. Furuta T., Shirai N., Sugimoto M. et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153–167. DOI: 10.2133/dmpk.20.153.
21. McColl K.E., Kennerley P. Proton pump inhibitors — differences emerge in hepatic metabolism. Dig Liver Dis. 202l;34(7):461–467. DOI: 10.1016/s1590-8658(02)80102-5.
22. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13 Suppl 3:27–36. DOI: 10.1046/j.1365-2036.1999.00022.x.
23. Fuhr U., Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie. 2002;57(9):595–601.
24. Besancon M., Simon A., Sachs G., Shin J.M. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438–22446. DOI: 10.1074/jbc.272.36.22438.
25. Ohning G.V., Walsh J.H., Pisegna J.R. et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther. 2003;17(9):1109–1114. DOI: 10.1046/j.1365-2036.2003.01573.x.
26. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99(2):345–351. DOI: 10.1016/0016-5085(90)91015-x.
27. Williams M.P., Sercombe J., Hamilton M.I., Pounder R.E. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12(11):1079–1089. DOI: 10.1046/j.1365-2036.1998.00418.x.
28. Pantoflickova D., Dorta G., Ravic M. et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507–1514. DOI: 10.1046/j.1365-2036.2003.01496.x.
29. Saitoh T., Fukushima Y., Otsuka H. et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002;16(10):1811–1817. DOI: 10.1046/j.1365-2036.2002.01348.x.
30. Pehlivanov N.D., Olyaee M., Sarosiek I., McCallum R.W. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther. 2003;18(9):883–890. DOI: 10.1046/j.1365-2036.2003.01776.x.
31. Luo J.Y., Niu C.Y., Wang X.Q. et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol. 2003;9(11):2583–2586. DOI: 10.3748/wjg.v9.i11.2583.
32. Skoczylas T., Sarosiek I., Sostarich S. et al. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322–328. DOI: 10.1023/a:1021983611768.
33. Jaworski T., Sarosiek I., Sostarich S. et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357–365. DOI: 10.1007/s10620-005-1611-3.
34. Hall J., Dodd S., Durkin M., Sloan S. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care. 2002;11(7 Suppl):14–18.
35. Gardner J.D., Gallo-Torres H., Sloan S. et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18(9):891–905. DOI: 10.1046/j.1365-2036.2003.01777.x.
36. Miner P.Jr., Orr W., Filippone J. et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332–1339. DOI: 10.1111/j.1572-0241.2002.05769.x.
37. Damiano A., Siddique R., Xu X. et al. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;48(4):657–662. DOI: 10.1023/a:1022812103923.
38. Kahrilas P.J., Miner P., Johanson J. et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50(11):2009–2018. DOI: 10.1007/s10620-005-3000-3.
39. Fock K.M., Teo E.K., Ang T.L. et al. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005;11(20):3091–3098. DOI: 10.3748/wjg.v11.i20.3091.
40. Bour B., Staub J.L., Chousterman M. et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21(7):805–812. DOI: 10.1111/j.1365-2036.2005.02413.x.
41. Robinson M., Fitzgerald S., Hegedus R. et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445–454. DOI: 10.1046/j.1365-2036.2002.01181.x.
42. Adachi K., Hashimoto T., Hamamoto N. et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18(12):1392–1398. DOI: 10.1046/j.1440-1746.2003.03190.x.
43. Pace F., Annese V., Prada A. et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37(10):741–750. DOI: 10.1016/j.dld.2005.04.026.
44. Archimandritis A.J., Nikolopoulou V., Kouklakis G. et al. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. Curr Med Res Opin. 2005;21(4):603–610. DOI: 10.1185/030079905X41444.
45. Kinoshita Y., Hongo M.; Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107(4):522–530. DOI: 10.1038/ajg.2012.19.
46. Kinoshita Y., Kato M., Fujishiro M. et al. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol. 2018;53(7):834–844. DOI: 10.1007/s00535-017-1417-z.
47. Fujimoto K., Hongo M.; Maintenance Study Group. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern Med. 2011;50(3):179–188. DOI: 10.2169/internalmedicine.50.4238.
48. Xia X.M., Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:327571. DOI: 10.1155/2013/327571.
49. Adachi K., Hashimoto T., Hamamoto N. et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18(12):1392–1398. DOI: 10.1046/j.1440-1746.2003.03190.x.
50. Pace F., Pallotta S., Bianchi Porro G. On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease. Dig Liver Dis. 2002;34(12):870–877. DOI: 10.1016/s1590-8658(02)80259-6.
51. Inamori M., Togawa J., Takahashi K. et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol. 2003;18(9):1034–1038. DOI: 10.1046/j.1440-1746.2003.03126.x.
52. Bytzer P., Blum A., De Herdt D., Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20(2):181–188. DOI: 10.1111/j.1365-2036.2004.01999.x.
53. Birbara C., Breiter J., Perdomo C., Hahne W. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol. 2000;12(8):889–897. DOI: 10.1097/00042737-200012080-00008.
54. Thjodleifsson B., Beker J.A., Dekkers C. et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000;45(5):845–853. DOI: 10.1023/a:1005548318996.
55. Dean B.B., Siddique R.M., Yamashita B.D. et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm. 2001;58(14):1338–1346. DOI: 10.1093/ajhp/58.14.1338.
56. Gerson L.B., Shetler K., Triadafilopoulos G. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liver Dis. 2005;37(9):651–658. DOI: 10.1016/j.dld.2005.04.013.
57. Johnston M.H., Eastone J.A., Horwhat J.D. et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005;62(6):842–848. DOI: 10.1016/j.gie.2005.05.008.
58. Chang A.B., Lasserson T.J., Gaffney J. et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011;2011(1):CD004823. DOI: 10.1002/14651858.CD004823.pub4.
59. Haddad I., Kierkus J., Tron E. et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57(6):798–807. DOI: 10.1097/MPG.0b013e3182a4e718.
60. Gibson P.G., Henry R.L., Coughlan J.L. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;2:CD001496. DOI: 10.1002/14651858.CD001496.
61. Oda K., Iwakiri R., Hara M. et al. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci. 2005;50(10):1921–1926. DOI: 10.1007/s10620-005-2962-5.
62. Tsugeno H., Mizuno M., Fujiki S. et al. A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand J Gastroenterol. 2003;38(5):456–461. DOI: 10.1080/00365520310002490.
63. Kłopocka M., Sinkiewicz A., Budzyński J. et al. Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole. Med Sci Monit. 2004;10(10):PI115–PI118.
64. Swiatkowski M., Budzyński J., Kłopocka M. et al. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med Sci Monit. 2004;10(9):CR524–CR529.
65. Molina-Infante J., Bredenoord A.J., Cheng E. et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65(3):524–531. DOI: 10.1136/gutjnl-2015-310991.
66. Dellon E.S., Gonsalves N., Hirano I. et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–692; quiz 693. DOI: 10.1038/ajg.2013.71.
67. Lucendo A.J., Arias Á., Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22.e1. DOI: 10.1016/j.cgh.2015.07.041.
68. Cheng E. Proton pump inhibitors for eosinophilic oesophagitis. Curr Opin Gastroenterol. 2013;29(4):416–420. DOI: 10.1097/MOG.0b013e32835fb50e.
69. Gisbert J.P., Khorrami S., Calvet X., Pajares J.M. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17(6):751–764. DOI: 10.1046/j.1365-2036.2003.01450.x.
70. Mario F.D., Dal Bo N., Aragona G. et al. Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. J Gastroenterol Hepatol. 2003;18(7):783–786. DOI: 10.1046/j.1440-1746.2003.03035.x.
71. Gambaro C., Bilardi C., Dulbecco P. et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig Liver Dis. 2003;35(11):763–767. DOI: 10.1016/s1590-8658(03)00458-4.
72. Yang K.C., Wang G.M., Chen J.H. et al. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J Formos Med Assoc. 2003;102(12):857–862.
73. Giannini E.G., Bilardi C., Dulbecco P. et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2006;23(2):281–287. DOI: 10.1111/j.1365-2036.2006.02756.x.
74. Wang H.H., Chou J.W., Liao K.F. et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World J Gastroenterol. 2005;11(11):1680–1984. DOI: 10.3748/wjg.v11.i11.1680.
75. Vakil N., Lanza F., Schwartz H., Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20(1):99–107. DOI: 10.1111/j.1365-2036.2004.02029.x.
76. Kawabata H., Habu Y., Tomioka H. et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2003;17(2):259–264. DOI: 10.1046/j.1365-2036.2003.01406.x.
77. Gisbert J.P., Pajares J.M. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21(7):795–804. DOI: 10.1111/j.1365-2036.2005.02418.x.
78. Ando T., Kato H., Sugimoto N. et al. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci. 2005;50(9):1625–1631. DOI: 10.1007/s10620-005-2907-z.
79. Ji S., Kim H.S., Kim J.W. et al. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J Gastroenterol Hepatol. 2006;21(9):1381–1387. DOI: 10.1111/j.1440-1746.2006.04314.x.
80. Kuo C.H., Wang S.S., Hsu W.H. et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265–272. DOI: 10.1111/j.1523-5378.2010.00761.x.
81. Viola M.J., Kondaveti S. To Compare the Safety and Efficacy of Three different, Proton Pump Inhibitors Omeprazole, Esomeprazole and Rabe-prazole in a Triple Drug Regimen in Patients with Peptic Ulcer Disease in the Eradication of H. Pylori Infection. Journal of Evidence based Medicine and Healthcare. 2015;2(13):2007–2026. DOI: 10.18410/jebmh/2015/285.
82. Sapmaz F., Kalkan I.H., Atasoy P. et al. A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. Am J Ther. 2017;24(4):e393–e398. DOI: 10.1097/MJT.0000000000000316.
83. Русяев В.Ю., Шептулин Д.А., Шульпекова Н.В., Шульпекова Ю.О. Рабепразол в лечении язвенной болезни двенадцатиперстной кишки и функциональной диспепсии. Медицинский совет. 2018;12:70–76. DOI: 10.21518/2079-701X-2018-12-70-76. [Rusyaev V.Yu., Sheptulin D.A., Shulpekova N.V., Shulpekova Yu.O. Rabeprazole in the treatment of duodenal ulcer desease and functional dyspepsia. Meditsinskiy sovet. 2018;12:70–76 (in Russ.)]. DOI: 10.21518/2079-701X-2018-12-70-76.
84. Gu L., Li S., He Y. et al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter. 2019;24(4):e12594. DOI: 10.1111/hel.12594.
85. Nguyen L.T., Nguyen V.B., Tran T.V. et al. Efficacy of Helicobacter pylori Eradication Based on Rabeprazole–Bismuth–Tetracycline–Tinidazole Regimen in Vietnamese Patients with Duodenal Ulcers. Gastroenterology Insights. 2022;13(4):365–376. DOI: 10.3390/gastroent13040036.
86. Morocutti A., Merrouche M., Bjaaland T. et al. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther. 2006;24(10):1439–1444. DOI: 10.1111/j.1365-2036.2006.03137.x.
87. Iwakiri R., Tominaga K., Furuta K. et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38(7):729–740. DOI: 10.1111/apt.12444.
88. Yap P.R., Mahadeva S., Goh K.L. Commentary: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38(10):1321–1322. DOI: 10.1111/apt.12497.
89. Sud R., Pebbili K.K., Desai S.A. et al. Dyspepsia — The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study). J Assoc Physicians India. 2023;71(4):36–43. DOI: 10.5005/japi-11001-0231.
90. Sugimoto M., Nishino M., Kodaira C. et al. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol. 2010;50(3):320–330. DOI: 10.1177/0091270009344983.
91. Nishino M., Sugimoto M., Kodaira C. et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci. 2010;55(6):1627–1636. DOI: 10.1007/s10620-009-0920-3.
92. Mizokami Y. Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan. World J Gastroenterol. 2009;15(40):5097–5102. DOI: 10.3748/wjg.15.5097.
93. Scarpignato C., Gatta L., Zullo A., Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases — A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. DOI: 10.1186/s12916-016-0718-z.
94. Плотникова Е.Ю., Исаков Л.К., Синькова М.Н., Гуляева Е.Н. Гастроинтестинальные кровотечения на фоне приема антикоагулянтов: риск возникновения, профилактика и лечение. Терапия. 2020;7:43–53. DOI: 10.18565/therapy.2020.7.43-53. [Plotnikova Ye.Yu., Isakov L.K., Sin'kova M.N., Gulyayeva Ye.N. Gastrointestinal bleeding against the background of taking anticoagulant drugs: risk of occurrence, prevention and treatment. Therapy. 2020;7:43–53 (in Russ.)]. DOI: 10.18565/therapy.2020.7.43-53.
95. Geus W.P. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol Suppl. 2000;(232):10–20. PMID: 11232484.
96. Green F.W. Jr, Kaplan M.M., Curtis L.E., Levine P.H. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978;74(1):38–43. PMID: 21830.
97. Patchett S.E., Enright H., Afdhal N. et al. Clot lysis by gastric juice: an in vitro study. Gut. 1989;30(12):1704–1707. DOI: 10.1136/gut.30.12.1704.
98. Uedo N., Takeuchi Y., Yamada T. et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007;102(8):1610–1616. DOI: 10.1111/j.1572-0241.2007.01197.x.
99. Hopkins A.M., Kichenadasse G., McKinnon R.A. et al. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2022;126(1):42–47. DOI: 10.1038/s41416-021-01606-4.
100. Mehta D.R., Maseeh A. Prevention of acid aspiration during surgery for cancer using I.V rabeprazole. Journal of Clinical Oncology. 2005;23(16):8275–8275. DOI: 10.1200/jco.2005.23.16_suppl.8275.
101. Evans C.E., Peng Y., Zhu M.M. et al. Rabeprazole Promotes Vascular Repair and Resolution of Sepsis-Induced Inflammatory Lung Injury through HIF-1α. Cells. 2022;11(9):1425. DOI: 10.3390/cells11091425.
102. Zhou Y., Chen S., Yang F. et al. Rabeprazole suppresses cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis. Biochem Pharmacol. 2021;188:114525. DOI: 10.1016/j.bcp.2021.114525.
103. Miyashita T., Shah F.A., Marti G.P. et al. Rabeprazole Impedes the Development of Reflux-Induced Esophageal Cancer in a Surgical Rat Model. Dig Dis Sci. 2011;56:1309–1314. DOI: 10.1007/s10620-010-1465-1.
104. Gu M., Zhang Y., Zhou X. et al. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 2014;8(4):1739–1744. DOI: 10.3892/ol.2014.2354.
105. Lodato F., Azzaroli F., Di Girolamo M. et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol. 2008;14(19):2980–2985. DOI: 10.3748/wjg.14.2980.
106. Mahmud N., Serper M., Taddei T.H., Kaplan D.E. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology. 2022;163(1):257–269.e6. DOI: 10.1053/j.gastro.2022.03.052.
107. Sablin O.A., Ratnikov V.A., Butenko E.V., Pakhomova I.G. Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita [Clinical aspects of using pariet in treating chronic pancreatitis]. Eksp Klin Gastroenterol. 2002;(5):73–76, 129 (in Russ.). PMID: 12619583.
108. Yamawaki H., Futagami S., Kaneko K., Agawa S. et al. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion. 2019;99(4):283–292. DOI: 10.1159/000492813.
109. Baldwin C.M., Keam S.J. Rabeprazole. Drugs. 2009;69:1373–1401. DOI: 10.2165/00003495-200969100-00007.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
